Sarcoidosis appears to follow two main trajectories, and clinical and treatment features at diagnosis may help predict whether the disease will resolve within the first few years or persist, according to a large study in Sweden involving more than 9,000 adult patients. About seven in 10 patients had few…

Cryptogenic organizing pneumonia, a rare lung disease, can develop in patients with sarcoidosis, according to a new case study from India. The report, “Cryptogenic Organizing Pneumonia with Sarcoidosis Overlap: An Atypical Case Study,” was published in the journal Case Reports in Medicine. Cryptogenic organizing pneumonia, also known…

Enrollment is complete in the dose-finding phase of a Phase 1b/2b clinical trial evaluating Xentria’s investigational therapy XTMAB-16 in adults with pulmonary sarcoidosis, and screening for the next phase is expected to start next fall. The Phase 1b/2 study (NCT05890729) enrolled 39 pulmonary sarcoidosis patients in four…

Researchers have developed a way of discriminating between patients who have sarcoidosis complicated by pulmonary hypertension (PH) and those without blood-pressure issues. The approach may improve the diagnosis of those who have sarcoidosis with PH. Their research, “Expression profiling elucidates a molecular gene signature for pulmonary hypertension…

Many people with moderate or severe pulmonary sarcoidosis — the target market for the investigational therapy efzofitimod — are highly burdened by the disease and are dependent on corticosteroids that can have serious side effects, according to real-world analyses. “New real-world evidence underscores the growing burden of patients…

A case study diagnosing pulmonary sarcoidosis in a patient complaining of chest pain and shortness of breath highlights the importance of including sarcoidosis in the differential diagnosis of chest pain. The study, “Sarcoidosis Presenting as Acute Respiratory Distress Syndrome,” was published in the journal Clinical Practice and…

A recent review discussed other options besides prednisone and methotrexate in treating sarcoidosis, including antimetabolites similar in action to methotrexate, antimalarial agents, adrenocorticotropic hormone (ACTH) gel, biological agents, and antimycobacterial therapy, which is normally used to treat tuberculosis. The review, “Sarcoidosis: treatments beyond prednisone and methotrexate,” was published…

“Sarc-a-what?” That’s usually the response we get when we tell someone we have sarcoidosis. “What’s that?” they ask, and then tune out the long explanation we begin to give. “Oh, good,” they add, “at least it’s not cancer.” And that’s precisely why we need Sarcoidosis Awareness Month. Throughout…

Hospitalization due to sarcoidosis has increased in the U.S., but in-hospital mortality has declined, according to a study from the University of Alabama at Birmingham (UAB). The data also showed that more than 30 percent of the hospitalized sarcoidosis patients had one or more cardiovascular complications. The research, “…

Nearly 1 in 10 people with pulmonary sarcoidosis also have heart involvement, or cardiac sarcoidosis, at the time of their initial diagnosis with the rare inflammatory disease occurring in the lungs, according to a study in Japan. Further, another 3.8% of patients subsequently develop cardiac sarcoidosis, the data…